Wells Fargo & Company F Star Therapeutics, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$4.09 - $6.86 $564 - $946	138 Added 104.55%	270 $1,000
Q3 2022 Nov 14, 2022	SELL	$5.41 - $6.74 $1.16 Million - $1.45 Million	-214,587 Reduced 99.94%	132 $1,000
Q2 2022 Aug 12, 2022	BUY	$2.18 - $6.39 $467,832 - $1.37 Million	214,602 Added 183420.52%	214,719 $1.34 Million
Q1 2022 May 16, 2022	BUY	$2.77 - $5.36 $2 - $5	1 Added 0.86%	117 $0
Q4 2021 Feb 14, 2022	BUY	$4.71 - $7.38 $32 - $51	7 Added 6.42%	116 $1,000
Q3 2021 Nov 15, 2021	SELL	$5.2 - $8.42 $31 - $50	-6 Reduced 5.22%	109 $1,000
Q2 2021 Aug 16, 2021	BUY	$6.57 - $10.71 $400 - $653	61 Added 112.96%	115 $1,000
Q1 2021 May 13, 2021	BUY	$7.09 - $13.84 $212 - $415	30 Added 125.0%	54 $1,000
Q4 2020 Feb 09, 2021	BUY	$1.03 - $10.39 $24 - $249	24 New	24 $0

44.7K

Ticker FSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,584,700
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.